Tackling Oral Insulin: A Niche Development Space
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
AstraZeneca-BMS Diabetes Deal Done: What’s Next On Biocon’s Oral Insulin?
AstraZeneca has declined an option agreement from Bristol-Myers Squibb on Indian drug maker Biocon’s oral insulin, raising questions about the fate of the candidate Biocon hopes will be a blockbuster.
For Some, Oral Insulin’s Allure Persists Despite Hurdles
The recent release of preliminary Phase III results for Generex Biotechnology Corp.’s buccal spray Oral-lyn put the challenging, but alluring for a few dogged developers, oral insulin development space back in the spotlight momentarily.
For Some, Oral Insulin’s Allure Persists Despite Hurdles
The recent release of preliminary Phase III results for Generex Biotechnology Corp.’s buccal spray Oral-lyn put the challenging, but alluring for a few dogged developers, oral insulin development space back in the spotlight momentarily.